1054 studies found for:    "Multiple sclerosis"
Show Display Options
Rank Status Study
1 Recruiting Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition
Conditions: Relapsing-remitting Multiple Sclerosis;   Secondary-progressive Multiple Sclerosis;   Primary-progressive Multiple Sclerosis
Interventions: Drug: estriol;   Other: Placebo;   Drug: Norethindrone;   Other: Progestin Placebo
2 Recruiting A Trial to Compare the Effectiveness of Two Rehabilitation Programs for Multiple Sclerosis Patients
Conditions: Primary Progressive Multiple Sclerosis,;   Secondary Progressive Multiple Sclerosis;   Relapsing-remitting Multiple Sclerosis,;   Demyelinating Autoimmune Diseases,;   Nervous System Diseases
Interventions: Behavioral: Combined program;   Behavioral: Physiotherapy in private practice
3 Recruiting A Phase 2b/3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis
Conditions: Multiple Sclerosis, Secondary Progressive;   Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Relapse Free
Interventions: Drug: masitinib;   Drug: placebo
4 Recruiting A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis
Conditions: Multiple Sclerosis, Remittent Progressive;   Multiple Sclerosis, Primary Progressive;   Relapsing-Remitting Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis;   Multiple Sclerosis
Interventions: Drug: Placebo;   Drug: fampridine (BIIB041)
5 Completed BG00012 Phase 2 Combination Study in Subjects With Multiple Sclerosis
Conditions: Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Relapsing-remitting;   Multiple Sclerosis
Intervention: Drug: BG00012
6 Completed Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron
Conditions: Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Interferon-1beta (Betaseron, BAY86-5046)
7 Recruiting A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis
Conditions: Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis;   Clinically Isolated Syndrome
Intervention:
8 Completed Natalizumab Treatment of Progressive Multiple Sclerosis
Conditions: Primary Progressive Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis
Intervention: Drug: Natalizumab
9 Recruiting Idebenone for Primary Progressive Multiple Sclerosis
Conditions: Multiple Sclerosis;   Primary Progressive Multiple Sclerosis
Intervention: Drug: Idebenone
10 Completed Safety Study of BIIB033 in Subjects With Multiple Sclerosis
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Interventions: Drug: BIIB033;   Drug: Placebo
11 Active, not recruiting Patient Research Cohort: Rapidly Evolving Multiple Sclerosis
Conditions: Relapsing-remitting Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis
Intervention:
12 Completed Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis
Conditions: Secondary Progressive Multiple Sclerosis;   Primary Progressive Multiple Sclerosis
Intervention: Biological: MIS416
13 Recruiting Plasma Exchanges in Multiple Sclerosis (MS) Relapses
Conditions: Multiple Sclerosis;   Multiple Sclerosis, Acute Relapsing
Interventions: Procedure: plasma exchange;   Procedure: sham exchanges procedure
14 Not yet recruiting A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis
Conditions: Secondary Progress Multiple Sclerosis;   Multiple Sclerosis
Interventions: Biological: NeuroVax;   Biological: IFA Placebo
15 Recruiting Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS)
Conditions: Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting
Intervention: Biological: DAC-HYP
16 Completed Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)
Conditions: Secondary Progressive Multiple Sclerosis;   Relapsing Forms of Multiple Sclerosis
Interventions: Drug: natalizumab;   Other: standard of care
17 Unknown  Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis
Conditions: Multiple Sclerosis, Chronic Progressive;   Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: RTL1000 (recombinant T cell receptor ligand);   Drug: RTL1000 Placebo
18 Completed Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS
Conditions: Relapsing-Remitting Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis;   Progressive Relapsing Multiple Sclerosis
Intervention: Biological: Autologous mesenchymal stem cell transplantation
19 Completed Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors
Conditions: Relapsing Remitting Multiple Sclerosis (RRMS);   Secondary Progressive Multiple Sclerosis (SPMS)
Intervention: Drug: Interferon beta-1b (Betaseron, BAY86-5046)
20 Active, not recruiting Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
Conditions: Autoimmune Diseases of the Nervous System;   Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis;   Disease Progression;   Brain Atrophy
Interventions: Biological: Tcelna;   Biological: Placebo

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years